 The clinical investigation will evaluate the safety and effectiveness of the TAXUSTMStent with 1 μgmm2 loaded drugstent surface area of paclitaxel incorporated into a moderate rate-release formulation of a triblock copolymer carrier system for treatment of de novo coronary artery lesions. 